This phase 2 study demonstrates that LY2951742, a fully humanised monoclonal antibody to CGRP, may be beneficial in migraine prevention and provides support for the role of calcitonin gene-related peptides in migraine pathogenesis (49). Here, CALCA is linked to migraine disorder.